NewLink Genetics (NASDAQ:NLNK) and RXi Pharmaceuticals (RXII) Head-To-Head Contrast

NewLink Genetics (NASDAQ: NLNK) and RXi Pharmaceuticals (NASDAQ:RXII) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Institutional & Insider Ownership

65.1% of NewLink Genetics shares are held by institutional investors. Comparatively, 10.7% of RXi Pharmaceuticals shares are held by institutional investors. 13.7% of NewLink Genetics shares are held by insiders. Comparatively, 5.7% of RXi Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for NewLink Genetics and RXi Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewLink Genetics 0 0 6 0 3.00
RXi Pharmaceuticals 0 0 0 0 N/A

NewLink Genetics presently has a consensus target price of $23.67, suggesting a potential upside of 199.20%. Given NewLink Genetics’ higher probable upside, analysts clearly believe NewLink Genetics is more favorable than RXi Pharmaceuticals.

Volatility & Risk

NewLink Genetics has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, RXi Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.

Earnings & Valuation

This table compares NewLink Genetics and RXi Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NewLink Genetics $28.71 million 10.24 -$71.95 million ($2.35) -3.37
RXi Pharmaceuticals $20,000.00 539.18 -$8.99 million ($10.85) -0.42

RXi Pharmaceuticals has lower revenue, but higher earnings than NewLink Genetics. NewLink Genetics is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


This table compares NewLink Genetics and RXi Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NewLink Genetics -250.60% -60.60% -47.48%
RXi Pharmaceuticals N/A -157.22% -102.29%


NewLink Genetics beats RXi Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

About RXi Pharmaceuticals

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with's FREE daily email newsletter.

Leave a Reply